Larry Miller, Apnimed CEO
January 3, 2023 05:35 AM EST
Financing
Startups

Ex­clu­sive: In lieu of an IPO in rocky biotech mar­ket, Ap­n­imed lines up $80M from ex­ist­ing in­vestors for two PhI­II tri­als

Kyle LaHucik

Senior Reporter

With the biotech mar­ket where it is, be­set by sink­ing stock prices for star­tups that went pub­lic dur­ing a pan­dem­ic boon and un­kind to new­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times